Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451279 | 1.00 | DHFR (0.37) | DHFRKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL26771211 | 0.91 | DHFR (0.36) | DHFRKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL30467566 | 0.82 | PDE10A (0.38) | DHFRPDE10ALRRK2KDR | |
| SCHEMBL24252687 | 0.82 | PDE10A (0.38) | DHFRPDE10ALRRK2KDR | |
| SCHEMBL30451651 | 0.81 | HPGD (0.44) | DHFRKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL24252889 | 0.81 | HPGD (0.44) | DHFRKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL24252389 | 0.79 | CYP11B1 (0.44) | ESR1ESR2KDRPIK3CA | |
| SCHEMBL30452090 | 0.79 | CYP11B1 (0.44) | ESR1ESR2KDRPIK3CA | |
| SCHEMBL24252302 | 0.78 | PDE10A (0.42) | DHFRPDE10ALRRK2 | |
| SCHEMBL30451917 | 0.78 | PDE10A (0.42) | DHFRPDE10ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | DHFR 1380/4885KDM4E 3923/4885ALDH1A1 653/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | DHFR 1380/4885KDM4E 3923/4885ALDH1A1 653/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | DHFR 1380/4885KDM4E 3923/4885ALDH1A1 653/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | DHFR 4573/4885KDM4E 2913/4885ALDH1A1 3178/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | DHFR 3196/4885KDM4E 4178/4885ALDH1A1 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.